Vaccines and antivirals for filoviruses

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

For more than 35 years the filoviruses, Ebola virus and Marburg virus, have caused sporadic outbreaks of hemorrhagic fever resulting in severe and often fatal disease in humans and nonhuman primates. Pathogenic Ebola and Marburg viruses are endemic in resource-poor regions in Central and West Africa and are also of concern as they have the potential for deliberate misuse as bioweapons. Although no vaccines or antivirals for filoviruses are currently licensed for human use, remarkable progress has been made in developing candidate preventive vaccines and antivirals against Ebola and Marburg viruses in nonhuman primate models. Two efficacious non-replicating vaccines tested in nonhuman primates consist of DNA or virus-like particles, while most of the effective vaccines are based on viral vectors including: recombinant adenoviruses, alphaviruses, paramyxoviruses, and rhabdoviruses. Successful post-exposure treatments against filoviruses to date consist of recombinant vesicular stomatitis virus vaccine vectors, antibody cocktail treatments, targeting virus genes or genomes through RNA interference, and use of a nucleoside analogue. While these vaccines and antivirals have shown great promise in nonhuman primate models, there are questions that remain in regard to providing broad-spectrum immunity and/or treatments for the different species of Ebola and strains of Marburg viruses.

Original languageEnglish (US)
Title of host publicationBiology and Pathogenesis of Rhabdo- and Filoviruses
PublisherWorld Scientific Publishing Co.
Pages587-620
Number of pages34
ISBN (Electronic)9789814635349
ISBN (Print)9789814635332
DOIs
StatePublished - Jan 1 2014

Fingerprint

Marburgvirus
Antiviral Agents
Vaccines
Ebolavirus
Primates
Rhabdoviridae
Alphavirus
Viruses
Central Africa
Vesicular Stomatitis
Western Africa
DNA Viruses
Gene Targeting
RNA Interference
Nucleosides
Adenoviridae
Virion
Disease Outbreaks
Immunity
Fever

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Mire, C., & Geisbert, T. (2014). Vaccines and antivirals for filoviruses. In Biology and Pathogenesis of Rhabdo- and Filoviruses (pp. 587-620). World Scientific Publishing Co.. https://doi.org/10.1142/9789814635349_0022

Vaccines and antivirals for filoviruses. / Mire, Chad; Geisbert, Thomas.

Biology and Pathogenesis of Rhabdo- and Filoviruses. World Scientific Publishing Co., 2014. p. 587-620.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mire, C & Geisbert, T 2014, Vaccines and antivirals for filoviruses. in Biology and Pathogenesis of Rhabdo- and Filoviruses. World Scientific Publishing Co., pp. 587-620. https://doi.org/10.1142/9789814635349_0022
Mire C, Geisbert T. Vaccines and antivirals for filoviruses. In Biology and Pathogenesis of Rhabdo- and Filoviruses. World Scientific Publishing Co. 2014. p. 587-620 https://doi.org/10.1142/9789814635349_0022
Mire, Chad ; Geisbert, Thomas. / Vaccines and antivirals for filoviruses. Biology and Pathogenesis of Rhabdo- and Filoviruses. World Scientific Publishing Co., 2014. pp. 587-620
@inbook{708fad502ac343a28b7290b41c036739,
title = "Vaccines and antivirals for filoviruses",
abstract = "For more than 35 years the filoviruses, Ebola virus and Marburg virus, have caused sporadic outbreaks of hemorrhagic fever resulting in severe and often fatal disease in humans and nonhuman primates. Pathogenic Ebola and Marburg viruses are endemic in resource-poor regions in Central and West Africa and are also of concern as they have the potential for deliberate misuse as bioweapons. Although no vaccines or antivirals for filoviruses are currently licensed for human use, remarkable progress has been made in developing candidate preventive vaccines and antivirals against Ebola and Marburg viruses in nonhuman primate models. Two efficacious non-replicating vaccines tested in nonhuman primates consist of DNA or virus-like particles, while most of the effective vaccines are based on viral vectors including: recombinant adenoviruses, alphaviruses, paramyxoviruses, and rhabdoviruses. Successful post-exposure treatments against filoviruses to date consist of recombinant vesicular stomatitis virus vaccine vectors, antibody cocktail treatments, targeting virus genes or genomes through RNA interference, and use of a nucleoside analogue. While these vaccines and antivirals have shown great promise in nonhuman primate models, there are questions that remain in regard to providing broad-spectrum immunity and/or treatments for the different species of Ebola and strains of Marburg viruses.",
author = "Chad Mire and Thomas Geisbert",
year = "2014",
month = "1",
day = "1",
doi = "10.1142/9789814635349_0022",
language = "English (US)",
isbn = "9789814635332",
pages = "587--620",
booktitle = "Biology and Pathogenesis of Rhabdo- and Filoviruses",
publisher = "World Scientific Publishing Co.",

}

TY - CHAP

T1 - Vaccines and antivirals for filoviruses

AU - Mire, Chad

AU - Geisbert, Thomas

PY - 2014/1/1

Y1 - 2014/1/1

N2 - For more than 35 years the filoviruses, Ebola virus and Marburg virus, have caused sporadic outbreaks of hemorrhagic fever resulting in severe and often fatal disease in humans and nonhuman primates. Pathogenic Ebola and Marburg viruses are endemic in resource-poor regions in Central and West Africa and are also of concern as they have the potential for deliberate misuse as bioweapons. Although no vaccines or antivirals for filoviruses are currently licensed for human use, remarkable progress has been made in developing candidate preventive vaccines and antivirals against Ebola and Marburg viruses in nonhuman primate models. Two efficacious non-replicating vaccines tested in nonhuman primates consist of DNA or virus-like particles, while most of the effective vaccines are based on viral vectors including: recombinant adenoviruses, alphaviruses, paramyxoviruses, and rhabdoviruses. Successful post-exposure treatments against filoviruses to date consist of recombinant vesicular stomatitis virus vaccine vectors, antibody cocktail treatments, targeting virus genes or genomes through RNA interference, and use of a nucleoside analogue. While these vaccines and antivirals have shown great promise in nonhuman primate models, there are questions that remain in regard to providing broad-spectrum immunity and/or treatments for the different species of Ebola and strains of Marburg viruses.

AB - For more than 35 years the filoviruses, Ebola virus and Marburg virus, have caused sporadic outbreaks of hemorrhagic fever resulting in severe and often fatal disease in humans and nonhuman primates. Pathogenic Ebola and Marburg viruses are endemic in resource-poor regions in Central and West Africa and are also of concern as they have the potential for deliberate misuse as bioweapons. Although no vaccines or antivirals for filoviruses are currently licensed for human use, remarkable progress has been made in developing candidate preventive vaccines and antivirals against Ebola and Marburg viruses in nonhuman primate models. Two efficacious non-replicating vaccines tested in nonhuman primates consist of DNA or virus-like particles, while most of the effective vaccines are based on viral vectors including: recombinant adenoviruses, alphaviruses, paramyxoviruses, and rhabdoviruses. Successful post-exposure treatments against filoviruses to date consist of recombinant vesicular stomatitis virus vaccine vectors, antibody cocktail treatments, targeting virus genes or genomes through RNA interference, and use of a nucleoside analogue. While these vaccines and antivirals have shown great promise in nonhuman primate models, there are questions that remain in regard to providing broad-spectrum immunity and/or treatments for the different species of Ebola and strains of Marburg viruses.

UR - http://www.scopus.com/inward/record.url?scp=84988628611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988628611&partnerID=8YFLogxK

U2 - 10.1142/9789814635349_0022

DO - 10.1142/9789814635349_0022

M3 - Chapter

AN - SCOPUS:84988628611

SN - 9789814635332

SP - 587

EP - 620

BT - Biology and Pathogenesis of Rhabdo- and Filoviruses

PB - World Scientific Publishing Co.

ER -